Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) CFO Robert Gagnon sold 7,783 shares of the business’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $22,959.85. Following the completion of the transaction, the chief financial officer directly owned 584,375 shares of the company’s stock, valued at approximately $1,723,906.25. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Opus Genetics Price Performance
IRD traded up $0.12 on Tuesday, hitting $3.46. 312,042 shares of the stock were exchanged, compared to its average volume of 939,716. The firm has a market capitalization of $286.11 million, a price-to-earnings ratio of -2.60 and a beta of 0.55. Opus Genetics, Inc. has a 12 month low of $1.04 and a 12 month high of $5.81. The business has a 50-day moving average of $3.91 and a two-hundred day moving average of $4.02.
Opus Genetics (NASDAQ:IRD – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59). The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.93 million. Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%. Equities research analysts expect that Opus Genetics, Inc. will post -1.08 earnings per share for the current fiscal year.
Institutional Trading of Opus Genetics
Analysts Set New Price Targets
Several research analysts have commented on IRD shares. Citizens Jmp restated a “market outperform” rating and set a $11.00 price objective on shares of Opus Genetics in a research report on Monday, June 15th. Guggenheim started coverage on Opus Genetics in a report on Thursday, June 4th. They issued a “buy” rating and a $16.00 target price on the stock. Leerink Partners initiated coverage on Opus Genetics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $10.00 price target on the stock. Zacks Research cut Opus Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, BTIG Research restated a “buy” rating and set a $12.00 price objective on shares of Opus Genetics in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Opus Genetics presently has an average rating of “Moderate Buy” and a consensus target price of $10.77.
Read Our Latest Stock Analysis on Opus Genetics
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Featured Stories
- Five stocks we like better than Opus Genetics
- Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
